Preclinical studies of the triazolo[1,5-a]pyrimidine derivative WS-716 as a highly potent, specific and orally active P-glycoprotein (P-gp) inhibitor

Multidrug resistance (MDR) is the main cause of clinical treatment failure and poor prognosis in cancer. Targeting P-glycoprotein (P-gp) has been regarded as an effective strategy to overcome MDR. In this work, we reported our preclinical studies of the triazolo[1,5-a]pyrimidine-based compound WS-71...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Sai-Qi, Teng, Qiu-Xu, Wang, Shuai, Lei, Zi-Ning, Hu, Hui-Hui, Lv, Hui-Fang, Chen, Bei-Bei, Wang, Jian-Zheng, Shi, Xiao-Jing, Xu, Wei-Feng, Liu, Hong-Min, Chen, Xiao-Bing, Chen, Zhe-Sheng, Yu, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366537/
https://www.ncbi.nlm.nih.gov/pubmed/35967279
http://dx.doi.org/10.1016/j.apsb.2022.03.023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366537/
https://www.ncbi.nlm.nih.gov/pubmed/35967279
http://dx.doi.org/10.1016/j.apsb.2022.03.023

Ejemplares similares